A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies
- 22 July 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21 (12), 823-830
- https://doi.org/10.1016/j.clml.2021.07.016
Abstract
No abstract availableFunding Information
- Sierra Oncology
This publication has 21 references indexed in Scilit:
- Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantationBritish Journal of Haematology, 2016
- Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotideCancer Chemotherapy and Pharmacology, 2014
- A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2013
- Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?Blood, 2012
- Targeting the B-Cell Lymphoma/Leukemia 2 Family in CancerJournal of Clinical Oncology, 2012
- Bcl-2-regulated apoptosis: mechanism and therapeutic potentialCurrent Opinion in Immunology, 2007
- Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB miceBlood, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- miR-15 and miR-16 induce apoptosis by targeting BCL2Proceedings of the National Academy of Sciences of the United States of America, 2005
- Killing cancer cells by flipping the Bcl-2/Bax switchCancer Cell, 2005